Are you a Business Owner?
Set up your Private Seller Account and create your listing todayGet Started Here
An investor required in the working production plant of heparin located in Tomsk, Russia. The plant doesn’t have competitors in the CIS. Planned return (ROI) is 40%. Payback period - less than 3 years.
Heparin, also known as unfractionated heparin (UFH), is a medication and naturally occurring glycosaminoglycan. As a medication it is used as an anticoagulant (blood thinner). Specifically it is also used in the treatment of heart attacks and unstable angina. It is given by injection into a vein or under the skin. Other uses include inside test tubes and kidney dialysis machines.
The global heparin market size was estimated at USD 6.49 billion in 2018 and is projected to expand at a CAGR of 1.6%. The CIS market size is about 50 million USD/year.
Production has started and is gaining momentum. Unique to the CIS technology, which was acquired in China and introduced into production. At the moment, in Russia and the CIS countries there is no full-cycle production of heparin. All heparin used in the pharmaceutical industry is imported from abroad, mainly from China. Production started on the production of heparin semifinished. Investments are required for the purchase of a line for the production of purified heparin and ensuring the procurement of raw materials under long-term contracts.
This investment is your chance to become an investor in a unique business that has every chance to become the main company in the CIS countries for the production and sale of heparin. Business is not dependent on the ruble exchange rate, because it focuses on goods whose value is calculated in US dollars.
Location: Tomsk, Russia
Area of industrial buildings: 1500 m2
Land area: 10,000 m2
Planned number of employees: 40 people
Invested in the project: $ 6 million
$ 3 million in technology and equipment
$ 3 million in the purchase of the building (1,500 m2) with a plot and its reconstruction
Investments required: $ 10 Million:
- $ 3 million in expansion of production (organization of production for the purification of heparin)
- $ 7 million to ensure uninterrupted supplies of raw materials and production needs
- Turnover after reaching full capacity: $ 25 million per year
- Profit - $ 15 million per year
- Profitability: 60%
- Return on investment for the investor (ROI): less than 3 years
Real Property Included
If you own a business and are considering selling, visit our Sell a Business section. Limited Free Trial available.Sell Your Business